The Moving Average Convergence Divergence (MACD) for CURE turned positive on October 09, 2026. Looking at past instances where CURE's MACD turned positive, the stock continued to rise in 42 of 46 cases over the following month. The odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on CURE as a result. In 85 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.
CURE moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CURE crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +13.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where CURE advanced for three days, in 290 of 323 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
The Aroon Indicator entered an Uptrend today. In 228 of 247 cases where CURE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
The 10-day RSI Indicator for CURE moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 29 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CURE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
CURE broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The RSI Indicator for MLPR moved out of oversold territory on October 05, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 22 similar instances when the indicator left oversold territory. In 21 of the 22 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for MLPR just turned positive on October 21, 2026. Looking at past instances where MLPR's MACD turned positive, the stock continued to rise in 47 of 52 cases over the following month. The odds of a continued upward trend are 90%.
Following a +3.99% 3-day Advance, the price is estimated to grow further. Considering data from situations where MLPR advanced for three days, in 306 of 330 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
MLPR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on October 19, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MLPR as a result. In 62 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.
MLPR moved below its 50-day moving average on September 21, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MLPR crossed bearishly below the 50-day moving average on September 25, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MLPR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for MLPR entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
| CURE | MLPR | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 89% | 2 days ago 76% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 75% |
| Advances ODDS (%) | 8 days ago 90% | 17 days ago 90% |
| Declines ODDS (%) | 4 days ago 90% | 9 days ago 83% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 60% |
A.I.dvisor indicates that over the last year, CURE has been closely correlated with LLY. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if CURE jumps, then LLY could also see price increases.
| Ticker / NAME | Correlation To CURE | 1D Price Change % | ||
|---|---|---|---|---|
| CURE | 100% | -1.28% | ||
| LLY - CURE | 73% Closely correlated | -1.01% | ||
| MRK - CURE | 66% Closely correlated | +1.07% | ||
| ABBV - CURE | 63% Loosely correlated | -1.48% | ||
| JNJ - CURE | 63% Loosely correlated | -0.61% | ||
| BMY - CURE | 59% Loosely correlated | -0.91% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| NVDU | 136.06 | 6.23 | +4.80% |
| Direxion Daily NVDA Bull 2X ETF (NVDU) | |||
| TEK | 37.75 | 0.72 | +1.95% |
| iShares Technology Opportunities Active ETF | |||
| AAAU | 40.75 | 0.16 | +0.39% |
| Goldman Sachs Physical Gold ETF (AAAU) | |||
| BNDP | 71.44 | 0.02 | +0.03% |
| Vanguard Core-Plus Bond Index ETF (BNDP) | |||
| PMMR | 27.53 | N/A | N/A |
| PGIM S&P 500 Max Buffer ETF March (PMMR) | |||